| Literature DB >> 35455443 |
Andreia Mendes1, Ana Armada1,2, Lília I L Cabral3,4, Patrícia S M Amado3,4, Lenea Campino1, Maria L S Cristiano3,4, Sofia Cortes1,2.
Abstract
Leishmaniasis remains one of the ten Neglected Tropical Diseases with significant morbidity and mortality in humans. Current treatment of visceral leishmaniasis is difficult due to a lack of effective, non-toxic, and non-extensive medications. This study aimed to evaluate the selectivity of 12 synthetic endoperoxides (1,2,4-trioxolanes; 1,2,4,5-tetraoxanes) and uncover their biochemical effects on Leishmania parasites responsible for visceral leishmaniasis. The compounds were screened for in vitro activity against L. infantum and L. donovani and for cytotoxicity in two monocytic cell lines (J774A.1 and THP-1) using the methyl thiazol tetrazolium assay. Reactive oxygen species formation, apoptosis, and mitochondrial impairment were measured by flow cytometry. The compounds exhibited fair to moderate anti-proliferative activity against promastigotes of the 2 Leishmania species, with IC50 values ranging from 13.0 ± 1.7 µM to 793.0 ± 37.2 µM. Tetraoxanes LC132 and LC138 demonstrated good leishmanicidal activity on L. infantum amastigotes (IC50 13.2 ± 5.2 and 23.9 ± 2.7 µM) with low cytotoxicity in mammalian cells (SIs 22.1 and 118.6), indicating selectivity towards the parasite. Furthermore, LC138 was able to induce late apoptosis and dose-dependent oxidative stress without affecting mithocondria. Compounds LC132 and LC138 can be further explored as potential antileishmanial chemotypes.Entities:
Keywords: 1,2,4,5-tetraoxanes; 1,2,4-trioxolanes; Leishmania donovani; Leishmania infantum; leishmaniasis; mode of action; reactive oxygen species; selectivity
Year: 2022 PMID: 35455443 PMCID: PMC9024893 DOI: 10.3390/ph15040446
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
CC50, IC50 and SI of synthetic trioxolanes, amphotericin B and miltefosine, against J774 A.1, THP-1 cell lines and the promastigote forms of L. infantum IMT 151 and L. donovani BD14 after 48 h incubation.
| Cytotoxicity | Promastigote’s Susceptibility | |||||||
|---|---|---|---|---|---|---|---|---|
| CC50 ± SD (µM) | IC50 ± SD (µM) | |||||||
| Compounds | J774A.1 | THP-1 |
| SI | SI (THP-1) |
| SI | SI (THP-1) |
| LC50 | 519.3 ± 139.5 | 712.8 ± 18.4 | 378.9 ± 2.8 | 1.4 | 1.9 | 353.6 ± 8.4 | 1.5 | 2.0 |
| LC93 | 12.0 ± 0.5 | 184.9 ± 16.1 | 435.0 ± 22.7 | 0.0 | 0.4 | 152.9 ± 22.4 | 0.1 | 1.2 |
| LC129 | 323.4 ± 24.5 | 355.9 ± 31.4 | 265.9 ± 13.3 | 1.2 | 1.3 | 242,4 ± 10.2 | 1.3 | 1.5 |
| LC131 | 34.1 ± 14.5 | 78.2 ± 14.1 | 321.1 ± 11.8 | 0.1 | 0.2 | 123.5 ± 19.0 | 0.3 | 0.6 |
| LC132 | 45.8 ± 19.9 | 99.8 ± 16.4 | 13.0 ± 1.7 | 3.5 | 7.7 | 14.3 ± 5.5 | 3.2 | 7.0 |
| LC136 | 113.0 ± 13.8 | 250.5 ± 4.1 | 434.2 ± 6.4 | 0.3 | 0.6 | 231.8 ± 28.4 | 0.5 | 1.1 |
| LC137 | 443.2 ± 44.0 | 3569 ± 22 | 137.1 ± 0.2 | 3.2 | 26.0 | 143.3 ± 16.5 | 3.1 | 24.9 |
| LC138 | 527.9 ± 54.0 | 2839 ± 15 | 125.4 ± 1.6 | 4.2 | 22.6 | 239.6 ± 34.8 | 2.2 | 11.9 |
| LC139 | 912.9 ± 70.7 | 115.2 ± 11.4 | 472.3 ± 39.2 | 1.9 | 0.2 | 506.8 ± 53.3 | 1.8 | 0.2 |
| LC140 | 677.6 ± 29.9 | 1399 ± 76 | 258.2 ± 6.4 | 2.6 | 5.4 | 460.1 ± 38.3 | 1.5 | 3.0 |
| LC146 | 1465 ± 13 | 3223 ± 72 | 491.7 ± 22.7 | 3.0 | 6.6 | 793.0 ± 37.2 | 1.8 | 4.1 |
| LC163 | 474.3 ± 83.5 | 753.4 ± 90.3 | 190.3 ± 21.6 | 2.5 | 4.0 | 531.6 ± 105.2 | 0.9 | 1.4 |
| AmB | 71.9 ± 5.4 | 23.2 ± 3.0 | 0.2 ± 0.0 | 467.7 | 151.0 | 0.3 ± 0.0 | 282.5 | 91.2 |
| Miltefosine | 94.4 ± 17.3 | 100.4 ± 12.1 | 148.7 ± 3.5 | 0.6 | 0.7 | 24.2 ± 10.0 | 3.9 | 4.1 |
IC50, half-maximal inhibitory concentration; CC50, half-maximal cytotoxic concentration; SI, selectivity index; Sis calculated from the ratio between the value of CC50 in J774A.1 and THP-1 cells, respectively, and IC50 of Leishmania spp. promastigotes; AmB, amphotericin B; SD, standard deviation.
IC50 and SI of most active synthetic trioxolanes and control drugs, intracelular amastigote forms of L. infantum IMT151 and L. donovani BD14 after 48 h incubation.
| Amastigote’s Susceptibility | ||||||
|---|---|---|---|---|---|---|
| Compounds |
| SI | SI (THP1) |
| SI | SI (THP-1) |
| LC132 | 13.2 ± 5.2 | 3.5 | 7.6 | 9.4 ± 0.1 | 4.9 | 66.3 |
| LC137 | 168.5 ± 8.9 | 2.6 | 21.2 | 88.3 ± 14.2 | 5.0 | 7.5 |
| LC138 | 23.9 ± 2.7 | 22.1 | 118.6 | 425.9 ± 25.5 | 1.2 | 10.6 |
| AmB | 0.3 ± 0.1 | 898.4 | 298.2 | 0.1 ± 0.0 | 898.4 | 40.4 |
| Miltefosine | 16.8 ± 11.7 | 5.6 | 6.0 | 13.3 ± 3.0 | 7.1 | 6.7 |
IC50, half-maximal inhibitory concentration; SI, selectivity index; SI calculated from the ratio between the value of CC50 in J774A.1 and THP-1 cells, respectively (see Table 1), and IC50 of Leishmania spp. amastigotes; AmB, amphotericin B; SD, standard deviation.
Figure 1Flow cytometry analysis of phosphatidylserine externalization after 24 h (A,B) and 48 h (C,D) treatment of L. infantum promastigotes with IC50 LC132 (13.0 µM), LC137 (137.0 µM), LC138 (125.4 µM) or AmB (0.2 µM) and 2 × IC50 LC132 (25.9 µM), LC137 (274.0 µM), LC138 (250.8 µM or AmB (0.3 µM). Percentages correspond to Annexin V (Annex) and Propidium iodide (PI) cell populations: Annex−/PI−, live cells; Annex+/PI−, early apoptotic cells; Annex+/PI+, late apoptotic cells; Annex−/PI+, necrotic cells. 2 mM H2O2 was used as control for apoptosis. Data are represented by mean ± standard error of mean (SEM) of three independent experiments, with triplicates. Asterisks represent statistically significant differences of apoptotic populations related to Control (non-treated parasites) * p < 0.05; *** p < 0.0001).
Figure 2Mitochondrial membrane potential of L. infantum promastigotes incubated for 24 h with (A) IC50 (13.0 µM LC132, 137.0 µM LC137, 125.4 µM LC138 and 0.2 µM AmB) and (B) 2 × IC50 (25.9 µM LC132, 274.0 µM LC137, 250.8 µM LC138 and 0.3 µM AmB). Results are presented as percentage of cells with red fluorescence at ~590 nm (JC-1 aggregates—black bars—indicating dye accumulation in mitochondria) and green fluorescence at ~519 nm (JC-1 monomers—grey bars—indicating membrane depolarisation). Positive control for membrane depolarization corresponds to parasites treated with 50 μM carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Data are represented by mean ± SEM of three independent experiments, with triplicates. Asterisks represent statistically significant differences of treated related to non-treated parasites; *** p < 0.0001.
Figure 3Effect of LC132, LC137, LC138 and AmB IC50 (13.0 µM, 137.0 µM, 125.4 µM and 0.2 µM, respectively) and 2 × IC50 (25.9 µM, 274.0 µM, 250.8 µM and 0.4 µM, respectively) on generation of ROS in L. infantum promastigotes, after (A) 5 h and (B) 24 h incubation. Parasites were labelled with CM-H2DCFDA. H2O2 (1 mM) was used as positive control. Data are represented by mean percentage of positive populations of FITC population ± SEM of three experiments, with triplicates. Asterisks represent statistically significant differences of treated, related to non-treated control * p < 0.01, *** p < 0.0001.
Structures of 1,2,4-trioxolanes and 1,2,4,5-tetraoxanes synthesized and concentration ranges employed in cytotoxicity and in vitro activity assays against Leishmania spp.
| Class | Compounds | Structures | ClogP a | Range of Concentrations (µM) | ||
|---|---|---|---|---|---|---|
| Cytotoxicity assay | Promastigote assay | Intracellular amastigote assay | ||||
| 1,2,4-trioxolanes | LC50 |
| 3.06 | 2156–33.7 | 538.9–134.7 | nd |
| LC93 |
| 3.30 | 2038–5.3 | 679.4–169.8 | nd | |
| LC129 |
| 3.86 | 1306-13.6 | 326.4–81.6 | nd | |
| LC131 |
| 3.81 | 1599–4.2 | 266.5–8.3 | nd | |
| LC132 |
| 4.05 | 1368–3.6 | 228.0–7.2 | 91.2–2.9 | |
| LC136 |
| 3.03 | 1728–46.0 | 576.0–15.3 | Nd | |
| 1,2,4,5-tetraoxanes | LC137 |
| 4.19 | 3569–66.9 | 356.9–89.2 | 285.5–8.9 |
| LC138 |
| 3.91 | 2839–53.2 | 567.9–142.0 | 425.9–13.3 | |
| LC139 |
| 2.12 | 2134–66.7 | 711.3–177.8 | nd | |
| LC140 |
| 3.04 | 3400–63.7 | 679.9–170.0 | nd | |
| LC146 |
| 3.10 | 3224–60.5 | 967.2–241.8 | nd | |
| LC163 |
| 2.94 | 2753–51.6 | 826.0–206.5 | nd | |
| AmB | 118.2–1.7 | 0.9–0.03 | 0.4–0.01 | |||
| Miltefosine | 1472–4.6 | 122.7–3.8 | 49.0–1.5 | |||
a Calculated using ALOGPS software (http://www.vcclab.org/lab/alogps/; accessed 14 November 2021); AmB, amphotericin B; nd, not done.
Figure 4Synthesis and structural representation of the 1,2,4-trioxolanes and 1,2,4,5-tetraoxanes investigated in this work. (A) Representation of the synthetic routes to the 1,2,4-trioxolanes; reagents and conditions: (a) Pyridine, MeONH2, MeOH, r.t; (b) ketone, O3, CH2Cl2/Pentane, −78 °C; (c) 1. LiAlH4, anhydrous Et2O, 0 °C, 1 h; 2. H2O; (d) Chloride derivative, TEA, Toluene, 45 °C; (e) 1. Triethyamine, mesyl chloride, THF, 3 h, 2. Amine, 60 °C; (f) Amine, AcOH, DCE, NaBH(OAc)3, r.t.; (B) Representation of the synthetic routes to 1,2,4,5-tetraoxanes; reagents and conditions: (g) SSA, CH3CN, H2O2 50% (w/w), 0 °C-rt; h) Ketone, SSA (2 eq), anhydrous CH2Cl2, rt, 2 h.